This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ICU Medical (ICUI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 5.88% and 4.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 48.44% and 13.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q3 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
ICU Medical (ICUI) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Gibraltar Industries, PJT Partners, ICU Medical, eXp World and Innovative Industrial Properties
by Zacks Equity Research
Zacks.com featured highlights include: Gibraltar Industries, PJT Partners, ICU Medical, eXp World and Innovative Industrial Properties
Buy These 5 Stocks on New Analyst Coverage Amid Coronavirus
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Zacks.com featured highlights include: eXp, American States Water, ICU Medical, Universal Technical Institute and SFL
by Zacks Equity Research
Zacks.com featured highlights include: eXp, American States Water, ICU Medical, Universal Technical Institute and SFL
New Analyst Coverage Brings 5 Stocks in Focus Amid Coronavirus
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
ResMed (RMD) Grows on SaaS Capabilities Amid Rising Expenses
by Zacks Equity Research
Within SaaS, ResMed (RMD) registers growing momentum in the Brightree service portfolio.
Steady Global Growth, Product Launches Aid Hill-Rom Business
by Zacks Equity Research
Hill-Rom (HRC) holds an encouraging 2022 outlook in terms of product launches.
ICU Medical (ICUI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 19.75% and 6.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 1.85% and 6.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Moving Average Crossover Alert: ICU Medical
by Zacks Equity Research
ICU Medical, Inc. (ICUI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ICU Medical (ICUI) Misses Q2 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of -4.78% and 1.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q2 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 18.35% and 4.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q1 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.